Abstract
Selective estrogen receptor modulators (SERMs) are steroidal or nonsteroidal compounds that can exhibit either estrogen-like agonistic effects or estrogen-antagonistic effects depending on the target tissue. While SERM actions in the breast, bone, and uterus have been well characterized, their effects in the brain are considerably less well understood. Previous work by our laboratory has demonstrated a beneficial effect of tamoxifen in the reduction of ischemic stroke damage in ovariectomized female rats. The present study utilized neuronal cell culture models to attempt to understand the mechanisms of tamoxifen-mediated neuroprotection. Neither physiologic doses of 17β-E2 nor clinically therapeutic doses of tamoxifen directly protected GT1-7 neurons or purified cultures of rat cerebrocortical neurons from several forms of cell death. Reverse transcriptase polymerase chain reaction and Western blot analysis revealed that GT1–7 neurons possessed both estrogen receptor-α (ERα) and ERβ mRNA and protein, whereas purified embryonic rat cortical neurons only expressed appreciable levels of ERα transcript and protein, with little to no expression of ERβ. In contrast to the lack of protection in the purified neuronal cultures, both 17β-E2 and tamoxifen significantly protected mixed glial/neuronal cortical cultures from cell death, suggesting that glia may facilitate 17β-E2-and tamoxifen-mediated neuroprotection. Furthermore, astrocyte-conditioned media and exogenous transforming growth factor-β1, a documented astrocyte-derived cytokine, were shown to rescue purified cortical neurons from cell death. Together, these findings support a role for astrocytes in neuroprotection and raise the intriguing possibility that astrocytes may help mediate the neuroprotective effect of 17β-E2 and tamoxifen.
Similar content being viewed by others
References
Simpkins, J. W., Rajakumar, G., Zhang, Y. Q., et al. (1997). J. Neurosurg. 87, 724–730.
Dubal, D. B., Kashon, M. L., Pettigrew, L. C., et al. (1998). J. Cereb. Blood Flow Metab. 18, 1253–1258.
Zhang, Y. Q., Shi, J., Rajakumar, G., Day, A. L., and Simpkins, J. W. (1998). Brain Res. 784, 321–324.
Rusa, R., Alkayed, N. J., Crain, B. J., et al. (1999). Stroke 30, 1665–1670.
Dubal, D. B. and Wise, P. M. (2001). Endocrinology 142, 43–48.
Alkayed, N. J., Crain, B. J., Traystman, R. J., and Hurn, P. D. (1999). Stroke 30, 274–279.
Wise, P. M. (2002). Trends Endocrinol. Metab. 13, 229–230.
Dhandapani, K. M. and Brann, D. W. (2002). Biol. Reprod. 67, 1379–1385.
Cholerton, B., Gleason, C. E., Baker, L. D., and Asthana, S. (2002). Drugs Aging 19, 405–427.
Fillit, H. M. (2002). Arch. Intern. Med. 162, 1934–1942.
Lonard, D. M. and Smith, C. L. (2002). Steroids 67, 15–24.
Mehta, S., Dhandapani, K. M., De Sevilla, L. M., Webb, R. C., Mahesh, V. B., and Brann, D. W. (2003). Neuroendocrinology 77, 44–50.
Dubal, D., Kashon, M. L., Pettigrew, L. C., et al. (1998). J. Cereb. Blood Flow Metab. 18, 1253–1258.
Kimelberg, H., Feustel, P., Jin, Y., et al. (2000). Neuroreport 11, 2675–2679.
Dluzen, D., McDermott, J. L., and Anderson, L. I. (2001). J. Neuroendocrinol. 13, 618–624.
Cheng, C. M., Cohen, M., Wang, J., and Bondy, C. A. (2001). FASEB J. 15, 907–915.
Cyr, M., Thibault, C., Morissette, M., Landry, M., and Di Paolo, T. (2001). Neuropsychopharmacology 25, 242–257.
Cyr, M., Morissette, M., Landry, M., and Di Paolo, T. (2001). Neuroreport 12, 535–539.
McMillan, P. J., LeMaster, A. M., and Dorsa, D. M. (2002). Brain Res. Mol. Brain Res. 103, 140–145.
Ernst, T., Chang, L., Cooray, D., et al. (2002). J. Natl. Cancer Inst. 94, 592–597.
Singer, C. A., Rogers, K. L., Strickland, T. M., and Dorsa, D. M. (1996). Neurosci. Lett. 212, 13–16.
Singer, C. A., Figueroa-Masot, X. A., Batchelor, R. H., and Dorsa, D. M. (1999). J. Neurosci. 19, 2455–2463.
Honda, K., Sawada, H., Kihara, T., et al. (2000). J. Neurosci. Res. 60, 321–327.
Honda, K., Shimohama, S., Sawada, H., et al. (2001). J. Neurosci. Res. 64, 466–475.
Harms, C., Lautenschlager, M., Bergk, A., et al. (2001). J. Neurosci. 21, 2600–2609.
Bae, Y. H., Hwang, J. Y., Kim, Y. H., and Koh, J. Y. (2000). J. Korean Med. Sci. 15, 327–336.
Regan, R. F. and Guo, Y. (1997). Brain Res. 764, 133–140.
Behl, C., Skutella, T., Lezoualc’h, F., et al. (1997). Mol. Pharmacol. 51, 535–541.
Goodman, Y., Bruce, A. J., Cheng, B., and Mattson, M. P. (1996). J. Neurochem. 66, 1836–1844.
Shughrue, P. J., Lane, M. V., and Merchenthaler, I. (1997). J. Comp. Neurol. 388, 507–525.
Wilson, M. E., Liu, Y., and Wise, P. M. (2002). Brain Res. Mol. Brain Res. 102, 48–54.
Wilson, M. E., Dubal, D. B., and Wise, P. M. (2000). Brain Res. 873, 235–242.
Cui, W., Allen, N. D., Skynner, M., Gusterson, B., and Clark, A. J. (2001). Glia 34, 272–282.
Buchanan, C., Mahesh, V. B., and Brann, D. W. (2000). Biol. Reprod. 62, 1710–1721.
Hosli, E., Jurasin, K., Ruhl, W., Luthy, R., and Hosli, L. (2001). Int. J. Dev. Neurosci. 19, 11–19.
Hosli, E., Ruhl, W., and Hosli, L. (2000). Int. J. Dev. Neurosci. 18, 101–111.
Azcoitia, I., Sierra, A., and Garcia-Segura, L. M. (1999). Glia 26, 260–267.
Donahue, J. E., Stopa, E. G., Chorsky, R. L., et al. (2000). Brain Res. 856, 142–151.
Dhandapani, K. M. and Brann, D. W. (2002). Biol. Reprod. 67, 1379–1385.
Dhandapani, K. M. and Brann, D. W. (2002). BMC Neurosci. 3, 6.
Brewer, G. J., Torricelli, J. R., Evege, E. K., and Price, P. J. (1993). J. Neurosci. Res. 35, 567–576.
Morris, E. J. and Geller, H. M. (1996). J. Cell Biol. 134, 757–770.
Lee, M., Hseih, M., Kuo, J., Yeh, F., and Huang, H. (1998). Neuroreport 9, 3451–3456.
D’Onofrio, M., Cuomo, L., Battaglia, G., et al. (2001). J. Neurochem. 78, 435–445.
McCarthy, K. D. and de Vellis, J. (1980). J. Cell Biol. 85, 890–902.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhandapani, K.M., Brann, D.W. Neuroprotective effects of estrogen and tamoxifen in vitro. Endocr 21, 59–66 (2003). https://doi.org/10.1385/ENDO:21:1:59
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:21:1:59